|
|
|
22.10.26 - 04:16
|
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight (ZeroHedge)
|
|
|
How The NYT Hid Big Pharma PR Titan Jack Leslie In Plain Sight
Authored by Paul D. Thacker via The DisInformation Chronicle,
New York Times reporter Sheryl Gay Stolberg wrote one of the most hilarious, misleading pieces I've seen in recent months, castigating the NIH for a new vaccine injury clinic based on a leaked statement by Jack Leslie, a senior advisor to the PR firm Weber Shandwick which represents most major vaccine manufacturers.
I'm not joking. This is the journalism I get for my paid subscription to the New York Times.
Like most senior executives at the global PR firm Weber Shandwick, Jack Leslie makes buckets of money helping corporations sell themselves and their products to the American public. In the last handful of years, Weber Shandwick's clients have included the bulk of the global vaccine giants including Pfizer, Moderna, GSK, Sanofi, Novartis, and Eli Lilly.
But when he's not raking in oodles of cash repping corporate America, Leslie also takes on some unpaid healthcare...
|
|
|
|
|
21.10.26 - 15:42
|
GSK Underweight (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für GSK vor den am 28. Oktober erwarteten Quartalszahlen auf "Underweight" mit einem Kursziel von 1700 Pence belassen. Analyst Zain Ebrahim verwies in einem am Mittwoch vorliegenden ......
|
|
|
|
|
|
|
21.10.26 - 11:48
|
GSK secures US approval for hepatitis B drug Hibsago (ShareCast)
|
|
|
Drugmaker GSK said on Wednesday that the US Food and Drug Administration had approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B in adults without cirrhosis, marking the first approval of an antisense oligonucleotid...
|
|
|
|
|
|
|
|
|
21.10.26 - 02:01
|
HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China (GlobeNewswire EN)
|
|
|
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct. 20, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive development and license agreement between HUTCHMED Limited (a subsidiary of the Company) and a subsidiary of GSK plc (“GSK”) has closed. The agreement grants the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.10.26 - 11:09
|
GSK Buy (DPA-AFX)
|
|
|
NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK nach Studiendaten für das Krebs-Konjugat Risvutatug Rezetecan mit einem Kursziel von 2500 Pence auf "Buy" belassen. Die Daten sollten das Vertrauen der Anleger steigern, ......
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
